The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume 5, Issue 7, Pages 543-546 (April 2006) DOI: 10.1016/j.eursup.2006.02.026 Copyright © 2006 Terms and Conditions

Fig. 1 Risk of developing osteoporosis after ADT is initiated in osteopenic men with hormone-refractory prostate cancer. LHRH=Luteinizing hormone-releasing hormone. From Weston et al. [1], with permission. European Urology Supplements 2006 5, 543-546DOI: (10.1016/j.eursup.2006.02.026) Copyright © 2006 Terms and Conditions

Fig. 2 BMD changes after 12 months of ADT. GnRH=Gonadotropin-releasing hormone; GnRH-a=GnRH analogue. From Mittan et al. [2], with permission. European Urology Supplements 2006 5, 543-546DOI: (10.1016/j.eursup.2006.02.026) Copyright © 2006 Terms and Conditions

Fig. 3 Kaplan–Meier estimate of fracture-free survival by type of treatment. GnRH=Gonadotropin-releasing hormone. From Shahinian et al. [3], with permission. European Urology Supplements 2006 5, 543-546DOI: (10.1016/j.eursup.2006.02.026) Copyright © 2006 Terms and Conditions

Fig. 4 Mean percent change from baseline BMD during ADT and pamidronate therapy. Data from Smith et al. [5]. European Urology Supplements 2006 5, 543-546DOI: (10.1016/j.eursup.2006.02.026) Copyright © 2006 Terms and Conditions

Fig. 5 Mean percent change from baseline lumbar spine BMD during zoledronic acid treatment at one year. GnRH=Gonadotropin-releasing hormone. Data from Smith et al. [6]. European Urology Supplements 2006 5, 543-546DOI: (10.1016/j.eursup.2006.02.026) Copyright © 2006 Terms and Conditions

Fig. 6 Mean percent change from baseline hip bone BMD during zoledronic acid treatment at one year. From Smith et al. [6], with permission. European Urology Supplements 2006 5, 543-546DOI: (10.1016/j.eursup.2006.02.026) Copyright © 2006 Terms and Conditions